CN113227072A - 2,4-二氨基嘧啶衍生物及其用途 - Google Patents

2,4-二氨基嘧啶衍生物及其用途 Download PDF

Info

Publication number
CN113227072A
CN113227072A CN201980085616.4A CN201980085616A CN113227072A CN 113227072 A CN113227072 A CN 113227072A CN 201980085616 A CN201980085616 A CN 201980085616A CN 113227072 A CN113227072 A CN 113227072A
Authority
CN
China
Prior art keywords
alkyl
halogen
alkynyl
alkenyl
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980085616.4A
Other languages
English (en)
Other versions
CN113227072B (zh
Inventor
张磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Zheye Biotechnology LLC
Original Assignee
Shanghai Zheye Biotechnology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zheye Biotechnology LLC filed Critical Shanghai Zheye Biotechnology LLC
Publication of CN113227072A publication Critical patent/CN113227072A/zh
Application granted granted Critical
Publication of CN113227072B publication Critical patent/CN113227072B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

本发明涉及一类2,4‑二氨基嘧啶衍生物，其药学上可接受的盐、水合物、溶剂化物或立体异构体，及其制备方法以及该类化合物单独或与其他药物联合使用在治疗具有ALK2激酶介导的病理学特征的疾病中的应用

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201980085616.4A 2018-12-26 2019-12-25 2,4-二氨基嘧啶衍生物及其用途 Active CN113227072B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018115946669 2018-12-26
CN201811594666.9A CN111362922A (zh) 2018-12-26 2018-12-26 2,4-二氨基嘧啶衍生物及其用途
PCT/CN2019/128245 WO2020135488A1 (zh) 2018-12-26 2019-12-25 2,4-二氨基嘧啶衍生物及其用途

Publications (2)

Publication Number Publication Date
CN113227072A true CN113227072A (zh) 2021-08-06
CN113227072B CN113227072B (zh) 2023-07-18

Family

ID=71126365

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811594666.9A Withdrawn CN111362922A (zh) 2018-12-26 2018-12-26 2,4-二氨基嘧啶衍生物及其用途
CN201980085616.4A Active CN113227072B (zh) 2018-12-26 2019-12-25 2,4-二氨基嘧啶衍生物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811594666.9A Withdrawn CN111362922A (zh) 2018-12-26 2018-12-26 2,4-二氨基嘧啶衍生物及其用途

Country Status (5)

Country Link
US (1) US20220177448A1 (zh)
EP (1) EP3904347A4 (zh)
JP (1) JP7219511B2 (zh)
CN (2) CN111362922A (zh)
WO (1) WO2020135488A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195956A1 (en) * 2008-09-02 2011-08-11 Matthew Burger Heterocyclic Kinase Inhibitors
CN105130959A (zh) * 2015-09-18 2015-12-09 上海吉铠医药科技有限公司 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
CN105308033A (zh) * 2013-03-14 2016-02-03 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) * 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AU2008296545B2 (en) * 2007-08-28 2011-09-29 Irm Llc 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
JP6339241B2 (ja) * 2014-05-30 2018-06-06 ベイジン・パール・バイオテクノロジー・リミテッド・ライアビリティ・カンパニー Ａｌｋキナーゼ阻害剤並びにその調製方法及び使用
EP3185868B1 (en) * 2014-08-25 2022-04-06 Salk Institute for Biological Studies Novel ulk1 inhibitors and methods using same
CN106699743B (zh) * 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195956A1 (en) * 2008-09-02 2011-08-11 Matthew Burger Heterocyclic Kinase Inhibitors
CN105308033A (zh) * 2013-03-14 2016-02-03 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法
CN105130959A (zh) * 2015-09-18 2015-12-09 上海吉铠医药科技有限公司 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用

Also Published As

Publication number Publication date
JP2022517745A (ja) 2022-03-10
JP7219511B2 (ja) 2023-02-08
WO2020135488A1 (zh) 2020-07-02
CN113227072B (zh) 2023-07-18
EP3904347A1 (en) 2021-11-03
US20220177448A1 (en) 2022-06-09
EP3904347A4 (en) 2022-09-14
CN111362922A (zh) 2020-07-03

Similar Documents

Publication Publication Date Title
JP7189956B2 (ja) Ｓｏｓ１阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
TWI765908B (zh) 苯並咪唑類化合物激酶抑制劑及其製備方法和應用
EP2365970B1 (en) Pyridazinones and their use as btk inhibitors
ES2477878T3 (es) Compuestos y composiciones de 5-(4-(aloalcoxi)fenil)pirimidin-2-amina como inhibidores de quinasas
ES2375151T3 (es) Derivados de bencimidazol sustituidos con pirimidina como inhibidores de prote�?na cinasa.
CN112955459A (zh) 双环肽配体和其用途
CA3183656A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
DK2970120T3 (en) HIS UNKNOWN PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USE
EP3294742B1 (en) New (5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h)quinazolin-2-yl)-(1h-pyrazol-5-yl)-amines and theri derivatives as igf-1r/1r inhibitors.
PT2099797E (pt) Compostos e composições como inibidores de proteína-quinase
WO2010068806A1 (en) Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2020035020A1 (zh) 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
CN110294761B (zh) 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
TWI580679B (zh) 雜芳基並嘧啶類衍生物、其製備方法和用途
JP2023513854A (ja) 大環状化合物およびその使用
EP3481824B1 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
JP2020511468A (ja) Ｍｋ２阻害剤の重水素化アナログおよびその使用
KR20200020888A (ko) 신규 퀴놀리논 화합물
TW202340209A (zh) 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
BR112020010004A2 (pt) compostos de pirazolopiridinona
BR112020010012A2 (pt) compostos de pirazolopiridinona
JP2006510727A (ja) キナーゼモジュレーター
CN113227072A (zh) 2,4-二氨基嘧啶衍生物及其用途
CN113227080B (zh) 2,4-二氨基嘧啶衍生物
WO2014114186A1 (zh) Jnk抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant